Genmab — Januar 2019
-
@ E L: I think they'll ask for approval of D-VRd asct based on Griffin, when we get the full data set (and data is good enough). Perseus is just to confirm data, and FDA will probably only give an approval on the condition that they make a large phase 3.
-
-
Genmab Shareholders: Register your email to receive electronic shareholder communications from Genmab incl. the calling to Genmab’s Annual General Meetings. Log on to the InvestorPortal & add your email under “My Profile”. The portal can be accessed from http://www.genmab.com .
-
Jo, de er hurtige på Børsen. Nyheden tjekkede lige ind som Breaking News på min telefon også. Absurd!
-
God aften ! Jeg er blevet lidt lyn på verastem i dette prisleje, og vil høre om der er nogle af herinde som har en mening om aktien. Hvad regnede vi med at ofa have af top salg estimat i cll/sll. Tænker at dette spg rammer bedre i GEN chatten end i biotek chatten.
-
Køøøb - det er helt vildt 330 % potentiale. https://www.tipranks.com/stocks/vstm/price-target
-
Næsten for godt til at være sandt ik?. Men det er en stor opgave at indarbejde et nyt drug i markedet specielt for så lille et selskab. har I et estimat for hvad ofa var estimeret til at sælge for i cll/sll ? kan ikke finde nogle salgsestimater på Copiktra.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind